Kaiyuan securities released a research report on January 28, saying that it maintained the buy rating of Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) (603896. Sh, latest price: 53.14 yuan). The reasons for rating mainly include: 1) steady growth of income and profit, and good results have been achieved in the national promotion of water testing; 2) The products have the core advantages of seed source, cultivation and processing; 3) Tablet dosage forms improve customer experience, reform distribution channels and promote national layout. Risk tip: the promotion outside the province is less than expected, and the policy implementation of traditional Chinese medicine is less than expected.
AI comments: Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) got two research reports from securities companies in recent month and bought one.
